BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

  March 31, 2025

   · 

  2 min read
• Press Releases

  CTNNB1 Foundation awarded €1M as Slovenia backs nonprofit gene therapy - a first step toward equitable cures for rare diseases

  March 31, 2025

   · 

  1 min read
• Press Releases

  IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

  March 31, 2025

   · 

  5 min read
• Press Releases

  Semaglutide 2.4 mg reduces burden of total cardiovascular events in people with established cardiovascular disease and overweight or obesity

  March 31, 2025

   · 

  9 min read
• Press Releases

  BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

  March 31, 2025

   · 

  10 min read
• Press Releases

  Traws Pharma Announces Management Updates

  March 31, 2025

   · 

  6 min read
• Press Releases

  bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

  March 31, 2025

   · 

  8 min read
• Press Releases

  Ozempic® (semaglutide) injection 1 mg showed improved functional outcomes and health-related quality of life in Phase 3 STRIDE trial in adults with type 2 diabetes and peripheral artery disease (PAD) presented at ACC 2025

  March 31, 2025

   · 

  8 min read
• Press Releases

  Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

  March 31, 2025

   · 

  10 min read
• Press Releases

  Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk

  March 31, 2025

   · 

  9 min read